KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Has the time come for routine use of PET/CT for guiding treatment of biochemical recurrence after radical prostatectomy? RE: JaniAB, et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet. 2021 May 22;55:1895-1904.

Ola Bratt

Scand J Urol 55(5) 420-421

PMID34633894
PMCID-
DOI10.1080/21681805.2021.1942192
发表日期2021-10-11
入排依据:The record describes a Phase 2/3 randomized controlled trial for prostate cancer, meeting basic oncology, human, randomized, and phase criteria. However, the abstract and metadata do not explicitly mention a time-to-event endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR) or a drug intervention. The intervention is PET/CT imaging to guide salvage radiotherapy, not a drug. Without clear evidence of a drug-containing arm and a time-to-event primary/key secondary endpoint, eligibility cannot be confirmed.
摘要

摘要

无摘要

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。